Agios Pharmaceuticals Seeks Accelerated FDA Approval for Mitapivat in Sickle Cell Disease Treatment

Agios Pharmaceuticals (AGIO) is making significant strides in advancing its drug mitapivat, marketed as AQVESME, for treating rare hematologic diseases. The company recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to seek accelerated approval for mitapivat in the treatment of sickle cell disease.

Promising Progress on Mitapivat

During a recent presentation at the 2026 RBC Capital Markets Global Healthcare Conference, CEO Brian Goff highlighted the promising early traction of AQVESME's launch in thalassemia. He expressed optimism for the sickle cell application after productive discussions with the FDA about the RISE UP trial data, which supports an expedited approval process based on the hemoglobin endpoint.

Goff underscored that the initial quarter of AQVESME's launch has been 'very strong,' paving the way for future developments in the treatment landscape for these chronic conditions.

Regulatory Pathway Encouraged

The regulatory package for the sNDA includes critical clinical data demonstrating the effectiveness and safety of mitapivat. Furthermore, Agios has agreed with the FDA on a confirmatory trial focusing on transfusion independence, set to enroll 159 patients over one year. This streamlined trial approach is designed to make participation more accessible, including for younger patients from age 12.

Upcoming Clinical Data Presentation

Agios plans to present detailed clinical trial data at the upcoming European Hematology Association Congress, which offers a platform to share insights on mitapivat's application in hematologic diseases. This congress is expected to provide additional momentum for the company as it navigates the future of its drug pipeline.